Focus on polypharmacy in schizophrenia: does anyone truly benefit?
Goff
Donald C
DC
Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA. goff@psych.mgh.harvard.edu
Freudenreich
Oliver
O
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D065127:Dopamine D2 Receptor Antagonists; D004359:Drug Therapy, Combination; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists